Alzheimer's disease (AD) is a neurodegenerative disorder, marked by senile plaques composed of amyloid-b (Ab) peptide, neurofibrillary tangles, neuronal loss and neuroinflammation. Previous works have suggested that systemic inflammation could contribute to neuroinflammation and enhanced Ab cerebral concentrations. The molecular pathways leading to these events are not fully understood. PKR is a pro-apoptotic kinase that can trigger inflammation and accumulates in the brain and cerebrospinal fluid of AD patients. The goal of the present study was to assess if LPS-induced neuroinflammation and Ab production could be altered by genetic PKR down regulation. The results show that, in the hippocampus of LPS-injected wild type mice, neuroinflammation, cytokine release and Ab production are significantly increased and not in LPS-treated PKR knock-out mice. In addition BACE1 and activated STAT3 levels, a putative transcriptional regulator of BACE1, were not found increased in the brain of PKR knock-out mice as observed in wild type mice. Using PET imaging, the decrease of hippocampal metabolism induced by systemic LPS was not observed in LPS-treated PKR knock-out mice. Altogether, these findings demonstrate that PKR plays a major role in brain changes induced by LPS and could be a valid target to modulate neuroinflammation and Ab production.
A lzheimer's disease (AD) is a neurodegenerative disorder marked by memory disturbances progressively associated with aphasia, apraxia, agnosia and behavioral symptoms. Currently, there is no cure for the disease and symptomatic treatment includes choline esterase inhibitors and glutamate antagonists. AD is neuropathologically characterized by senile plaques made of the accumulation of Ab-peptides, neurofibrillary tangles formed by hyperphosphorylated tau protein, synaptic and neuronal losses and neuroinflammation including the presence of activated microglia 1 . The cause of the disease is not known but according to the amyloid cascade hypothesis, the toxicity of Ab or Ab oligomers could lead to detrimental consequences for neurons and to neuroinflammation 2 . Brain inflammation is a key component of the pathological lesions detected in the brain of patients suffering from AD 3, 4 . Astrocytic and microglial cell reactions are often detected surrounding senile plaques. It has been postulated that neuroinflammation could exacerbate brain lesions leading to synaptic dysfunctions and neuronal degeneration. The Ab-peptide can trigger microglial cell activation inducing the release of the pro-inflammatory cytokines such as TNFa or IL1-b 5 . Recent works have suggested that systemic inflammation could exacerbate or even drive neuronal dysfunction associated with dementia and that the kinases PKR and JNK could play a role in these molecular events 6 . Common molecular pathways linking Diabetes Mellitus and AD were recently proposed: mild systemic inflammation could trigger abnormal consequences in the brain including impaired neuronal insulin signalling, synapse degradation and memory disturbances associated with the release of TNFa and IL1-b. Systemic inflammation is also known to modify microglial phenotypes and systemic manipulations of inflammation can improve the disease status by negatively alter this progression 7 . This hypothesis stimulated our interest in determining if pro-inflammatory factors such as the ubiquitous kinase PKR, acting peripherally and in the brain, could contribute to abnormal molecular signals leading to increased neuroinflammation and AD brain lesions during systemic inflammation.
PKR is a pro-apoptotic kinase that controls the initial step of protein translation through the phosphorylation of the eukaryotic initiation factor 2 alpha (eIF2a) 8 . PKR is involved in several cellular pathways including innate immunity and defence against viruses. PKR can sequentially induced cell survival and death pathways 9 . PKR also modulates the synthesis of pro-inflammatory factors via the activation of the NF-kB (nuclear factor k light-chain-enhancer of activated B cells) pathway after direct interaction with IKKb (inhibitor of nuclear factor kappa-B kinase subunit beta) 10 . The PKR inhibitor C16 can prevent IL-1b and neuronal apoptosis induced by quinolinic acid administration 11 . PKR is also involved in the control of the inflammasome and HMGB1 (high-mobility group protein B1) release 12 . This kinase is highly expressed in degenerative neurons in AD brains and can be activated in primary neuronal cultures by Ab 13, 14 . In addition the levels of phosphorylated PKR are highly increased in the cerebrospinal fluid (CSF) of patients suffering from AD or Mild Cognitive Impairment 15 and can correlate with the cognitive decline in AD patients 16 . Since PKR is elevated in AD CSF and brains and can modulate neuroinflammatory signals, we sought to determine if PKR could control brain inflammation and Ab accumulation after systemic LPS administration in wild-type (WT) mice and PKR -/-mice. Previous studies reported neuroinflammation induction and Abincrease after systemic LPS administration 17 . By use of this experimental model, we further investigated whether PKR played a role in triggering the molecular pathways leading to these pathological processes. The results show that PKR genetic down-regulation reduces neuroinflammation and Ab accumulation.
Results

Systemic injection of LPS induces brain PKR phosphorylation.
To assess the consequences of repeated LPS injections on PKR activation, we first performed immunofluorescence analyses of pPKR staining in sagittal slices of WT mice brain exposed to saline or LPS. In WT mice treated with saline solution, we observed a weak cytoplasmic pPKR Thr446 staining in hippocampus and cortex ( Figure 1A-B) . Repeated injections of LPS lead to a dramatic increase of number of pPKR Thr446 positive cells ( Figure 1C ) in both hippocampus and cortex of WT mice. We found a similar increase in hippocampus by evaluating with imageJ software the intensity of staining ( Figure 1D ). To evaluate the potential proapoptotic effects of PKR in this neuroinflammatory model, we have measured by immunoblotting the cleavage by caspase-3 of the nuclear enzyme poly ADP-ribose polymerase (PARP). LPSinduced PKR activation did not lead to a cleavage of PARP protein (Supplementary Figure 1) .
PKR down-regulation prevents hippocampal LPS-induced microglial activation and cytokines production. Microglia and astrocytes are known to be major sources of neuro-inflammation and are strongly activated by intra-peritoneal LPS injection. Our immunohistofluorescence using a specific marker of microglial cells activation, IBA1 (Ionized calcium-binding adaptor molecule 1) confirmed this finding (Figure 2A ). Quantified immunofluorescence analyses of IBA1 positive microglia in the hippocampus, using ImageJ software, revealed a 64% increase of the staining intensity in LPStreated mice compared to untreated mice ( Figure 2B Figure 2) .
Analyses of IBA1 staining in hippocampus of LPS-treated PKR -/-mice revealed a significant decrease of microglial activation (243%) compared to LPS-treated WT mice ( Figure 2B ). Similar variations were found on astrocytes activation, quantified by enumerating GFAP (glial fibrillary acidic protein) -positive cells in hippocampus (Supplementary Figure 2) . Finally, we assessed hippocampal cytokine TNF-a mRNA level by quantitative real time PCR. As expected, the mRNAs level of TNF-a is dramatically increased in LPS-treated mice (1890%). In PKR -/-mice, LPS-induced TNF-a appears less overexpressed (199%) ( Figure 2C ). In addition using Elisa, we also found that PKR down regulation abolished the increase of brain IL-6 levels induced by systemic LPS injection ( Figure 2D ).
BACE1 upregulation and Ab production induced by intra-peritoneal LPS injection is reversed in PKR -/-mice. Intraperitoneal LPS administration is known to induce a brain Ab accumulation in WT mice. To confirm this previous observation in our specific model of repeated LPS injection, we first assessed hippocampal APP processing by immunoblotting analyses of mature BACE1 ( Figure 3A -B) and APP proteins ( Figure 3A and C) and then by evaluating soluble Ab level with a specific Elisa assay ( Figure 3D ). Our results are consistent with observations obtained in other LPS models, with a significant increase of mature BACE1 protein level (158%) and Ab production (1184%). By contrast, there were no changes in APP protein. To test whether upregulation of BACE1 levels by neuroinflammation occurs only at a translational level, we measured mRNA levels of BACE1 by real-time quantitative PCR. Levels of BACE1 messengers from LPS-treated WT mice were 1.8 fold higher than those of untreated-WT mice ( Figure 3E ). Interestingly, LPS-treated PKR -/-mice exhibit significantly reduced levels of soluble Ab and of BACE1 mRNA and protein compared to LPS-treated WT.
As PKR activation could also trigger tau phosphorylation in stress conditions through glycogen synthase kinase -3b (GSK3-b) phosphorylation on tyrosine 216 (pGSK3-b), we performed immunoblot analysis of pGSK3-b, GSK3-b total protein, tau total protein and phosphorylated tau on different sites, such as AT180 (supplementary Figure 4A ). Our results reveal a significant increase of pGSK3-b/ GSK3-b ratios (134%) (Supplementary Figure 4B ) which is not associated with an increase of tau phosphorylation on AT180 (supplementary Figure 4C ), AT8 or AT270 (not shown).
Increase of activated STAT3 level by systemic LPS administration is PKR dependent. Previous in vitro researches have shown that stress-induced eIF2a phosphorylation at serine 52 by PKR could increase BACE1 translation and lead to Ab over-production. Immunoblotting for phosphorylated eIF2a (peIF2a) and eIF2a total protein ( Figure 4A ) enabled the assessment of the role of the eIF2a activation in LPS-induced amyloidogenic signaling. It showed that peIF2a Ser52 /eIF2a ratio is not affected by systemic LPS administration ( Figure 4B ), suggesting an alternative PKRdependent pathway for BACE1 upregulation. Activation of the transcription factor STAT3 by phosphorylation on tyrosine 705 is able to regulate BACE1 expression in neurons. Immunoblot analysis of pSTAT3 Tyr705 /STAT3 ratio revealed a statistically significant increase (143%) in LPS-treated WT mice versus saline-injected mice ( Figure 4C ). It is worth noting that such increase was no longer observed after PKR down regulation.
PKR inhibition prevents hippocampal hypometabolism after LPS systemic challenge. Motion matrix from the CT to the MR was applied to the PET scan (automatically coregistered to the CT scan) ( Figure 5A ). Volumes of interest were retreived on the PET scan ( Figure 5B ) and semi-quantification of regional radiotracer uptake, expressed as a percentage of Injected Dose/g, was normalised to the cerebellar uptake. An average was calculated and the region was then considered as striata. The regional tracer uptake normalized the cerebellar one, was averaged among the mice within each group. We reported in Figure 5 the impairment of metabolism in a subregion of the hippocampus, the Ammon's horn.
In this specific region, the LPS-WT animals had a statistically significant metabolic drop when compared to the controls. However, in the PKR -/-mice, the metabolism of the Ammon's horn did not differ whether the mice were under LPS treatment or not ( Figure 5C ).
Discussion
Our results show that systemic inflammation produced by LPS administration can induce neuroinflammation and increased brain Ab production in wild-type mice. In addition, the genetic invalidation of the kinase PKR in PKR -/-mice leads to the reduction of neuroinflammation and Ab accumulation in these mice treated with systemic LPS. Although in this model phosphorylated tau was not modified in LPS treated mice as compared to non-treated mice, activated GSK3b, and activated STAT3 were increased in LPS treated mice. PKR down regulation has prevented the increased brain levels of these enzymes in LPS injected mice. Several questions are to be addressed.
Firstly, is there a modification of peripheral inflammation in PKR -/-mice underpinning the reduction of neuroinflammation detected in PKR -/-mice treated with repeated LPS administration? An answer may be found by further assessing mRNA levels of TNF-a or other cytokines (IL-1b, IL-6…) in the spleen or liver of wild-type and PKR -/-injected animals. A second question is how can PKR control brain inflammation? Previous studies have shown that LPS injection induces the activation of the innate immune system with production of blood cytokines such as TNF-a and IL-1b that are able to enter the brain in regions with weak blood brain barrier or by active transport through the endothelium among several mechanisms 18 . Consequently, cytokines can activate microglial cells that can also release local cytokines and can induce a spreading of neuroinflammation. PKR has been shown to participate in the production of inflammatory signals either by directly activating IKKb and the NF-kB signaling 19 or by partially controlling the inflammasome 20 . In our study, TNFa is decreased in injected PKR -/-brain as compared to WT mice suggesting that the invalidation of PKR has reduced the ability of microglial cells to synthesize inflammatory cytokines and transfer neuro-inflammatory signals. This effect is also revealed in the hippocampus by the reduction of activated microglial cells in LPS-injected PKR -/-mice as compared to LPS-injected WT mice. The result showing that brain PKR is activated in LPS-injected WT mice as compared to control mice validate this model of neuroinflammation and strengthen the putative role of PKR signaling in the control of cytokines release and microglial activation.
An additional question is how PKR can control Ab production in this model? Previous reports have revealed that systemic LPS administration can increase Ab levels in the brain of injected mice 21, 22 . Our results have confirmed these results in wild-type mice but have also found that PKR genetic invalidation partially prevented brain Ab accumulation in PKR -/-mice. It is not known if this event is linked to increased Ab production or reduced Ab degradation but Ab accumulation is associated with a clear modification of BACE1 protein levels that could lead to increased Ab production. There are at least two mechanisms that could link BACE1 and PKR activation. The first one is associated with the peculiar upstream open reading frame of BACE1, which leads to an increased mRNA expression under the control of eIF2a 23, 24 . Surprisingly, 24 hours after the last LPS administration, eIF2a phosphorylation was not found augmented in WT mice whereas phosphorylated PKR was increased. This could be due to the specific activation of eIF2a phosphatases one day after the last LPS injection. As opposed to what previous authors have observed, a recent paper has shown that inhibition of eIF2a phosphorylation did not alter BACE1 levels and Ab production in neuronal cultures or in transgenic mice 25 . This finding argues in favor of a PKR-dependent and eIF2a-independent mechanism controlling BACE1 levels in neurons. The second mechanism is associated with the control of BACE1 mRNA synthesis by STAT3 26 . Our results have revealed that brain activated STAT3 levels are increased in LPS-injected wild-type mice and not in LPS-injected PKR -/-mice. A previous data has shown that PKR can control the activation of STAT3 and the triggering of the A last question is why phosphorylated tau is not modified in the brain of LPS-injected mice. A previous study has shown that LPS administration in 3xTg AD mice exacerbates tau phosphorylation at the AT8 antibody site 27 . In our study although we observed a pGSK3- b increase in LPS-treated mice which was not associated with increased tau phosphorylation at the AT8 site. As already described for eIF2a phosphorylation, one can suggest that specific phosphatases are activated 24 h after the LPS administration and further studies will be needed to determine the time course of brain tau phosphorylation and dephosphorylation in this model. The process of tau phosphorylation could also differ in the brains of wild-type mice and transgenic mice after LPS injection. Our [
18 F]FDG-microPET study revealed that LPS injection in wild-type mice decreases metabolism in the hippocampus (Amon's Horn) but this effect was not seen in LPS-injected PKR -/-mice. It has been shown previously that sepsis can induce neuroinflammation and a reduction of cerebral metabolism in experimental animals 28 . The authors have demonstrated that in LPS-treated rats, cerebral glucose uptake was reduced in cortical areas and not in the hippocampus but animals received a single LPS injection. The fact that PKR genetic down regulation prevents the modification of neuronal metabolism could be due to the reduced brain neuroinflammation, to the reduction of the observed Ab accumulation or to the inhibition of pro-apoptotic pathway associated with PKR activation 29 although cleaved PARP levels, indicative of caspase 3 activation, were not modified in LPS-injected wild-type mice.
There are some limitations in our study. All the assessments were performed only at a single time point, 24 hours after the last LPS injection. Further studies will have to decipher if a recovery phase is observed one or two weeks after the induced systemic inflammation either concerning neuroinflammation or Ab accumulation. Since LPS induces a sickness syndrome, it is difficult to properly assess behavioral disturbances at the time point of our study but cognitive tests could be performed in the future during the recovery phase after LPS administration. Finally the use of new and specific PKR inhibitors in the future will be needed to determine if these results can be reproduced using a pharmacological approach. Previous studies have shown that systemic infections can exacerbate the evolution of AD patients 30, 31 . In this experimental study, we have shown that systemic inflammation can lead to brain PKR activation and Ab accumulation ( Figure 6 ). In addition, phosphorylated PKR is increased in the brains and CSF of AD or mild cognitive impairment (MCI)-due to AD patients and CSF PKR levels could correlate with cognitive decline. The reason for increased levels of PKR in AD brain is not known but could be associated with cytokine release or Ab toxicity and also could be exacerbated by systemic infections or inflammation. An earlier data has revealed that PKR activation could negatively control memory formation in experimental animals 32 . All these findings argue for an early neuroinflammatory process in AD which could be secondarily driven by systemic inflammation and underline the fact that PKR could be a valid new therapeutic target to reduce neuroinflammation and AD brain lesions, to afford neuroprotection and improve memory in affected individuals 33 .
Methods
Animals. All experimental protocols used in this study were approved by the Animal Experiments Committee of the INSERM Institut du Fer à Moulin (UMR-S839) and were performed in accordance with the guidelines of the French Agriculture and Forestry Ministry for handling animals (decree 87849, license A75-05-22). C57BL/6J wild type (WT) and PKR knockout (PKR -/-) mice (male, 10 weeks old) were used for all experiments. WT mice were purchased from Janvier (Le Genest St Isle, France).
PKR -/-mice, generated by disruption of exons 2 and 3 of the PKR gene 34 were provided by Dr RCC Chang, The University of Hong Kong, Li Ka Shing Faculty of Medicine, Department of Anatomy, Laboratory of Neurodegenerative Diseases.
All mice were held in a temperature-controlled room under a 12 hours light/dark cycle and had access to food and water ad libitum. Animal experiments were performed in accordance with the guidelines of the French Agriculture, Food and Forestry Ministry for handling animals (decree 87849, license A75-05-22).
Mice received daily intraperitoneal (i.p) injections of either saline or LPS from Escherichia coli 0111:B4 (Millipore, Molsheim, France), 1 mg/kg for 3 days. Twentyfour hours after the last injection, 20 mice were taken to the in vivo imaging facility whereas all others were deeply anesthetized with a lethal dose of pentobarbital and intracardially perfused with cold PBS. Brains were then collected in ice, dissected and
Immunoblotting and ELISA. Cortex and hippocampus were homogenized and sonicated in a radioimmunoprecipitation assay buffer (RIPA buffer) containing 10 mM NaPi pH 7.8, 59 mM NaCl, 1% Triton, 0.5% DOC, 0.1% SDS, 10% glycerol and extemporaneous addition of protease inhibitor cocktail (Roche, Penzberg, Germany), 1 mM Na3VO4 and 0.1 mM calyculin A (Sigma, St Louis, MO) as phosphatase inhibitors. Tissues were then centrifuged at 15 000 g for 10 minutes and protein concentration is determined with Micro BCA Protein Assay Reagent Kit (Thermo scientific, Cergy-Pontoise, France) using manufacturer's protocol.
For immunoblotting, after denaturation (96uC, 5 minutes, in b-mercaptoethanol with 150 g/L SDS, 0.3 M Tris-HCl pH 6.8, 25% glycerol and bromophenol blue), protein samples (25 to 50 mg) were separated on Tris-glycine polyacrylamide gels (Bio-Rad, Nanterre, France) and transferred onto nitrocellulose membranes (GE Healthcare, Chalfont St. Giles, UK) in 25 mM Tris pH 8.3, 200 mM glycine and 20% ethanol. Membranes were incubated 30 minutes in blocking buffer (1 X TBS with 5% milk), and then overnight at 4uC with primary antibodies. Rabbit anti-BACE1 (Santa Cruz, Danvers, MA, USA), rabbit anti-APP (Cell Signaling, Beverly, MA, USA), mouse anti-phosphorylated GSK3b Tyr216 (pGSK3b Tyr216 ) (BD Transduction Laboratories, San Jose, CA, USA), mouse anti-GSK3b (Cell Signaling), mouse AT180 (Thr231/Ser235) (Thermo Scientific), mouse anti-Tau (Thermo Scientific), rabbit anti-pSTAT3 Tyr705 (Cell Signaling), rabbit anti-STAT3 (Cell Signaling), rabbit antiactin (Sigma, St. Louis, MO) and mouse anti-tubulin (Santa Cruz) were used as primary antibodies. IR Dye 700DX conjugated anti-mouse IgG and IR Dye 800 CW conjugated anti-rabbit IgG (Rockland Immunochemical Inc., Gilbertsville, PA, USA) were used as secondary antibodies. Protein bands were revealed by use of the Odyssey imaging system (Li-Cor Biosciences, Lincoln, NE, USA) and quantified with the Multigauge software (Fuji-film, Tokyo, Japan).
Ab 1-42 levels were quantified using a mouse colorimetric Ab 1-42 ELISA kit (Covance Inc., Princeton, NJ, USA) following the manufacturer's instructions. Optical absorbance was detected using a 96 well plate reader at 450 nm. Ab levels were calculated from a standard curve.
IL-6 levels were quantified using a mouse colorimetric IL-6 ELISA kit (Signosis Inc.,Santa Clara, CA, USA) following the manufacturer's instructions. Optical absorbance was detected using a 96 well plate reader at 450 nm. IL-6 levels were calculated from a third-order polynomial regression curve.
Immunohistofluorescence. After fixation in 4% paraformaldehyde, brains were incubated in 30% sucrose, frozen in Jung tissue medium (Leica, Nanterre, France) and sectioned using a cryostat. Sagittal sections (10 mm) were washed in PBS with 0.25% gelatin and 25% Triton and incubated at 4uC for 24 h with rabbit anti-ionized binding molecule adaptor 1 (Iba1) (Wako, Osaka, Japan) and rabbit anti-pPKR Thr446 (Abcam, Cambridge, UK) and at room temperature for 2 h with secondary antibodies donkey anti-rabbit Cy3 (Jackson Laboratory, Bar Harbor, Maine, USA). Standard epifluorescence images were acquired on a Leica DMRD microscope using a high resolution camera (Coolsnap HQ). The Metamorph software (Roper Scientific, Sarasota, FL, USA) was used for image acquisition. All quantitative image analyses were performed by using NIH ImageJ software, as previously described 35 . Quantification was limited to the areas corresponding to the cortex and hippocampus. DAPI and the cyanine 3 pictures were both background corrected using the rolling ball method. A threshold was then chosen using the 'Auto threshold' function of ImageJ. Cells were subsequently evaluated by defining a region of interest and by running the 'Analyze particles' imageJ function. Afterward, quantification of positive cells was performed using the Colocalization plug-in.
Quantitative RT-PCR. Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) from cortex and hippocampus. Transcriptor First Strand cDNA Synthesis kit (Roche) with a combination of random hexamers and oligo(dT) priming to avoid 39-bias in the cDNAs was used to synthesize the first strand cDNA from samples with an equal amount of total RNA (1 mg), according to the manufacturer's instructions. cDNA samples were forwarded to amplification with Real Time ready Assays (Roche) using LightCyclerH96 Instrument (Roche). Each assay included gene specific primers for TNFa (tumor necrosis factor, alpha), BACE-1 (beta-site APP cleaving enzyme 1) and GAPDH (glyceraldehydes-3-phosphate dehydrogenase) and a Universal ProbeLibrary (UPL) Probe, which was a short FAM-labeled (6-carboxyfluorescein) hydrolysis probe containing locked nucleic acid (LNA) (Roche). Mus Musculus BACE1 primers [forward 59-AAGCTGCCGTCAAGTCCAT-39 and reverse 59-CTGCTCCCCTAGCCAAAAG-39], TNFa primers [forward 59-TCTTCTCATTCCTGCTTGTGG-39 and reverse 59-GGTCTGGGCCATAGAACTGA-39] and GAPDH primers [forward 59-AGCTTGTCATCAACGGGAAG-39 and reverse 59-TTTGATGTTAGTGGGGTCTCG-39] were used. cDNA amplification was carried out as follows: denaturation at 95uC for 10 seconds, followed by 45 cycles of denaturation at 95uC for 10 seconds and primer annealing-extension step at 60uC for 30 seconds, ending with a cooling step at 37uC for 30 seconds. All assays were performed in triplicates. Relative levels and gene copy numbers were calculated (normalized to GAPDH) using the previously described deltaCp method 36 .
[ 18 F]FDG in vivo imaging. Eleven C57BL/6J wild type (WT) and nine PKR knockout (PKR -/-) mice were taken to imaging facility the night before imaging and kept at room temperature with free access to food and water up to 6 hours prior to radiotracer injection when food was no longer accessible. Positron emission tomography scans were performed in a microPET (Inveon, Siemens). A bolus injection of [ 18 F]FDG (131/-1.5 MBq; 150 ml in volume) was administered intraperitoneally while the animal was conscious. After injection, the mouse was returned to its cage to allow for biodistribution for approximately 45 min. Then, the mouse was anesthetized with isoflurane (5% for induction and 1,5% for maintenance in 100% O 2 at a flow rate of 1 L/min) using a nose cone and placed in a prone position on the platform of the scanner. With the help of a laser alignment device attached to the scanner, the mouse was positioned so that the center of the field corresponded to the brain. A CT scan (80 KV and 500 mA) was run right before the mouse moved into the PET field of view. PET scanning was initiated at 60 min after radiotracer injection. Total scanning duration was 15 min. For co-registration purposes, a 7 T T2-weighted magnetic resonance imaging C57BL/6J brain scan was used to improve cerebral regional delineation on brain PET imaging. Data from the scanner were formatted into 3 frames, 2D-OSEM reconstructed and corrected for scatter and attenuation. Counts detected by the scanner were converted into MBq/mL by use of Inveon Research Workflow (IRW version 3.0, Siemens). This software enables multimodality imaging coregistration and allows manual drawing of volumes of interest (VoIs). MR spatial resolution allows a rather precise identification of several cerebral regions so we drew on the hippocampus on both hemispheres, as shown on the figure 5b. A background VoI was also drawn outside the mouse body. MR whole brain scan was manually coregistered to the CT-scan.
Statistical Analysis. All experiments were performed independently at least three times. All data were normalized and analyzed using the StatView software (Fuji-film). The paired sign test or Student's t-test was used to compare the experimental and control groups. Results were considered significant for a value of p , 0.05 using the student test.
